research MP74-11 TRENDS IN THE PHARMACOTHERAPY OF NOCTURIA, 2016-2021: ANALYSIS OF A LARGE MULTI-INSTITUTIONAL RESEARCH NETWORK
Nocturia cases increased, but medication use declined, suggesting under-treatment.
Search
for
Sort by
Research
150-180 / 1000+ resultsresearch UP-02.28
The document aimed to understand how certain treatments affect blood vessel growth in rat prostates.
research Effect of castration and finasteride on urinary oxalate excretion in male rats
Castration and finasteride lower urinary oxalate in male rats, potentially treating urolithiasis.
research Asociación entre disfunción eréctil y funcionalidad del subsistema conyugal en pacientes con hiperplasia prostática benigna
Erectile dysfunction is linked to marital issues in patients with benign prostatic hyperplasia.
research Tamsulosin and Solifenacin : A Dynamic Duo in BPH Management
Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
research Finasteride with Doxazosin to Reduce BPH Progression
research Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men
Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.
research The Reduction of Male Lower Urinary Tract Symptoms Is Associated With a Decreased Risk of Death
Improving symptoms of male urinary problems may lower the risk of death.
research Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
Medications for enlarged prostate can cause sexual side effects like reduced libido, erectile dysfunction, and ejaculatory problems.
research Experience of using of Sonirid Duo in treatment of patients with BPH
Sonirid Duo effectively treats benign prostatic hyperplasia.
research A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.
Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
research Patterns of Care for Newly Diagnosed Benign Prostatic Hyperplasia in the United States
Most care for benign prostatic hyperplasia follows guidelines, but 5-α reductase inhibitors are often used incorrectly.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Association Between Urolithiasis and Hidradenitis Suppurativa: A Retrospective Cohort Study
People with hidradenitis suppurativa have a higher risk of kidney stones.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
research 5α-Reductase Inhibitors Do Not Prevent the Development and Progression of Urothelial Cancer: In Vitro Evidence
5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Retraction of: Bansal and Arora. J Endourol. Epub ahead of print; DOI: 10.1089/end.2016.0696
The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research UP-02.011 Biofeedback Treatment for Dysfunctional Voiding Diagnosed in Adulthood
Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.
research BPH: epidemiology and comorbidities.
BPH is common in older men and often occurs with other age-related health issues.
research 1746 INCREASED SERUM C-REACTIVE PROTEIN LEVELS IMPLIES CHRONIC INFLAMMATION IS INVOLVED IN MEN WITH BENIGN PROSTATIC HYPERPLASIA AND PREDOMINANT STORAGE LOWER URINARY TRACT SYMPTOMS
Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
research AB40. Sexual side effects of medical treatment of BPH
BPH treatments can cause sexual side effects affecting quality of life.
research Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
research How Many Drugs for LUTS Due to BPH are Too Many?
research Les Visiteurs des malades
5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
research Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study
5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.
research Hormonal manipulation of benign prostatic hyperplasia
Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.